Clinical evaluation of Himplasia in Benign Prostatic Hyperplasia: An Open Clinical Trial

This was an open clinical trial undertaken in 25 elderly male patients in the age group of 45-90 years diagnosed with Benign Prostatic Hyperplasia (BPH) in the Department of Shalya Shalakya, Sir Sundarlal Hospital, Institute of Medical Sciences, Banaras Hindu University, Varanasi. Himplasia was administered at a dose of 2 tablets, twice daily for a period of 3 months. All the patients were followed-up for 3 months at an interval of 4 weeks. They were evaluated on IPSS score along with uroflowdynamics. Himplasia significantly relieved the symptoms of BPH along with improvement in urinary flow rates and reduction in post-void residual urine. INTRODUCTION Benign prostatic hyperplasia (BPH) is a disorder, which leads to urinary symptoms in elderly males. More than 90% of the males over 80 years of age have histological evidence of BPH (Fang-Liu, 1993). Worldwide more than 25 million of elderly men suffer from moderate to severe degree symptoms of BPH. The symptoms of BPH include poor flow of urine, difficult micturition, intermittent flow, dribbling, poor bladder emptying, hesitancy, urinary frequency, nocturia, urge incontinence etc., which affects the physical activities, mental health leading to deterioration of the “quality of the life” of the patients. Medical therapy is effective in reducing the symptoms, prostate size and improving the quality of life of the patients. As the disease affects elderly males, they carry risks for surgery due to other geriatric problems like associated hypertension, diabetes, ischemic heart diseases etc. Medical therapy is supported worldwide in part, by limitations of the surgery and post-operative complications (Lepor et al., 1993). Many herbal formulations are getting popularized worldwide for the management of BPH (Fitzpatrick and Lynch 1995). Himplasia is a polyherbal formulation, which has proved beneficial in reducing the symptoms of prostatic hyperplasia. This clinical trial was planned to substantiate its therapeutic benefits and to evaluate the efficacy in various clinical and uroflowmetric parameters in patients with BPH. MATERIAL AND METHODS This was an open clinical trial undertaken in 25 male patients in the age group of 45-90 years diagnosed with Benign Prostatic Hyperplasia in the Department of Shalya Shalakya, Sir Sundarlal Hospital, Institute of Medical Sciences, Banaras Hindu University, Varanasi. Himplasia was administered at a dose of 2 tablets, twice daily for a period of 3 months. All the patients were followed-up for 3 months at an interval of 4 weeks. Clinical, biochemical and uroflowmetry was repeated at three months following completion of treatment. The objective of this study was to evaluate the benefits of Himplasia in terms of the following parameters. Decrease of AUA score • • •